WEKO3
アイテム
Mechanisms of CAR-T Cell Exhaustion and its Application for Next-generation CAR-T Cells to Overcome Solid Tumors
https://dmu.repo.nii.ac.jp/records/2000630
https://dmu.repo.nii.ac.jp/records/2000630fa4d3778-f804-4d5b-8dc4-b5bd5777ce98
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
DKMJ-4-2-1.pdf (567 KB)
|
.png)
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||
|---|---|---|---|---|---|---|---|---|
| タイトル | ||||||||
| タイトル | Mechanisms of CAR-T Cell Exhaustion and its Application for Next-generation CAR-T Cells to Overcome Solid Tumors | |||||||
| 言語 | en | |||||||
| 言語 | ||||||||
| 言語 | eng | |||||||
| キーワード | ||||||||
| 言語 | en | |||||||
| 主題Scheme | Other | |||||||
| 主題 | chimeric antigen receptor | |||||||
| キーワード | ||||||||
| 言語 | en | |||||||
| 主題Scheme | Other | |||||||
| 主題 | co-stimulatory signal domain | |||||||
| キーワード | ||||||||
| 言語 | en | |||||||
| 主題Scheme | Other | |||||||
| 主題 | energy metabolism | |||||||
| キーワード | ||||||||
| 言語 | en | |||||||
| 主題Scheme | Other | |||||||
| 主題 | T cell exhaustion | |||||||
| キーワード | ||||||||
| 言語 | en | |||||||
| 主題Scheme | Other | |||||||
| 主題 | transcription factor | |||||||
| 資源タイプ | ||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||
| 資源タイプ | journal article | |||||||
| アクセス権 | ||||||||
| アクセス権 | open access | |||||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||||
| 著者 |
Nunoya, Jun-ichi
× Nunoya, Jun-ichi
|
|||||||
| 書誌情報 |
en : Dokkyo Medical Journal 巻 4, 号 2, p. 93-106, 発行日 2025-04-25 |
|||||||
| 記事種別 | ||||||||
| 値 | Review | |||||||
| 内容記述 | ||||||||
| 内容記述タイプ | Abstract | |||||||
| 内容記述 | Chimeric antigen receptor (CAR) is a chimeric molecule consisting of an extracellular antigen recognition domain and an intracellular signal transduction domain. Although the idea about CAR-T cells has been considered for quite some time, it has not been easy to show its efficacy. However, recently developed immunotherapy using CAR-T cells targeting CD19 is rapidly attracting attention because of its remarkable response rate against B-cell malignancies. CAR-T cell therapy has been approved in several countries, and used as standard treatment for relapsed or refractory cases. Under these circumstances, along with immune checkpoint inhibitors, CAR-T cell therapy is now recognized as the fourth treatment option for cancer. On the other hand, it has become clear that CAR-T cell therapy targeting CD19 also has a high relapse rate after complete remission. In addition, the response rate for solid tumors has still been low. One of the reasons for this is known to be exhaustion of CAR-T cells. It is essential to improve the function and characteristics of CAR-T cells in order to improve the response rate of CAR-T therapy and to expand its application to solid tumors. In this paper, the mechanisms of CAR-T cell exhaustion and its contributing factors are summarized. Also, the recent strategies to overcome CAR-T cell exhaustion will be reviewed for developing the nextgeneration CAR-T cells against solid tumors. | |||||||
| 言語 | en | |||||||
| 出版者 | ||||||||
| 出版者 | Dokkyo Medical Society | |||||||
| ISSN | ||||||||
| 収録物識別子タイプ | EISSN | |||||||
| 収録物識別子 | 2436-522X | |||||||
| 書誌レコードID | ||||||||
| 収録物識別子タイプ | NCID | |||||||
| 収録物識別子 | AA12941861 | |||||||
| DOI | ||||||||
| 関連タイプ | isIdenticalTo | |||||||
| 識別子タイプ | DOI | |||||||
| 関連識別子 | https://doi.org/10.51040/dkmj.2024-015 | |||||||
| 出版タイプ | ||||||||
| 出版タイプ | VoR | |||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||
